Citadel Advisors’s Nuvectis Pharma NVCT Stock Holding History

Citadel Advisors’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$606K	Buy	+78,425	New	+$672K	﹤0.01%	8828
2025 Q2	–	Sell	-10,344	Closed	-$93.8K	–	14265
2025 Q1	$101K	Buy	+10,344	New	+$74.5K	﹤0.01%	11445
2024 Q3	–	Sell	-14,937	Closed	-$94.6K	–	14919
2024 Q2	$94.6K	Buy	+14,937	New	+$102K	﹤0.01%	10996
2023 Q3	–	Sell	-28,028	Closed	-$448K	–	14829
2023 Q2	$448K	Buy	+28,028	New	+$447K	﹤0.01%	8189
2022 Q3	–	Sell	-35,069	Closed	-$393K	–	13288
2022 Q2	$393K	Buy	+35,069	New	+$434K	﹤0.01%	9175

Other funds holding NVCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's NVCT Position: Q1 2026 in Review

Citadel Advisors opened a new position in Nuvectis Pharma (NVCT) in Q1 2026: 78,425 shares worth $606K. The stake represents ﹤0.01% of the portfolio and ranks #8828 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in NVCT as recently as Q1 2025.

Citadel Advisors first reported a position in NVCT in Q2 2022 and has held it in 5 quarters since. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

Citadel Advisors held 78,425 shares of Nuvectis Pharma worth $606K as of Q1 2026.
Nuvectis Pharma was a new Citadel Advisors position in Q1 2026.
Nuvectis Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8828 holding.
Citadel Advisors first reported a position in Nuvectis Pharma in Q2 2022 and has held it in 5 quarters since.
62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.